

Curriculum Vitae



Personal data:

Name	Abdel Naser Zaid
Date of birth	05/11/1968
Sex	Male
Nationality	Palestinian
Marital status	Married
Correspondence address	An-Najah National University College of Pharmacy Nablus P.O.Box 7 West-Bank Palestine (Via Israel) Home Tel + 972-9-2341039 Cellular Tel: +972-59-839197 Fax. + 972-9-2316230 e-mail: anzaid@najah.edu zaid_n52@hotmail.com

Education:

- Oct.97-Jul.1998 Post-Doctoral fellowship. Medco company [King Pharmaceutical, (North Caroline, USA)].
- 1994-1997 Ph.D in Pharmaceutical Sciences/Chemistry and Pharmaceutical Technology, Adviser, Prof. P. G. Baraldi, full professor of Pharmaceutical chemistry and Cosmetic Technology. Department of Pharmaceutical Sciences, University of Ferrara, Italy.

Jul.1994	Proclaimed Doctor in Pharmaceutical Chemistry & Technology, Final Grade: 110/110.
1993-1994	Experimental Theses in Clinical Pharmacology, Adviser, Professor S.Tanganelli, full professor of Clinical Pharmacology, Department of Clinical & Experimental Medicine, University of Ferrara, Italy.
1988-1994	Degree in Chemistry & Pharmaceutical Technology, Faculty of Pharmacy University of Ferrara, Italy.
1985-1987	Al Tawjihi, Silat - Aldaher -West Bank (Scientific branch)

Languages:

-Arabic	Mother Language
-Italian	Excellent
-English	Very Good.

Published Papers:

1. **A.N. ZAID**, R. AL- Ramahi, A. Abu Ghoush, N. Jaradat, M. Musmar. Frequency and Attitudes of using hair dyes among Palestinian women. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 5(2): 485-488.
2. **A. N. Zaid** , T. Rinno, N. Jaradat, S. Jodeh and S. Khammash. . Interchangeability between multisource Paracetamol tablets marketed in Palestine. Is there a quality reason for a higher price? Eastern Mediterranean Health Journal. 2013; 19(6): 542-546.
3. Abualhasan MN, Batrawi N, **Zaid AN**, Watson DG. A validated and stability indicating HPLC method for analysis of diminazene aceturate and antipyrine combination in a ready injectable solution. Drug Res (Stuttg). 2013; 63(6): 300-4.
4. **Zaid AN**, Natour S, Qaddomi A, Abu Ghoush A. Formulation and in vitro and in vivo evaluation of film-coated montelukast sodium tablets using Opadry® yellow 20A82938 on an industrial scale. Drug Design, Development and Therapy. 2013;7, 83 – 91.
5. **Abdel Naser Zaid**. Formulation and evaluation of the chemical stability of Povidone-Iodine in some trademarks cleaning formulations. Int J Pharm Pharm Sci. 2013; 5(1): 46-48.
6. **Abdel Naser Zaid**, Rowa' J. Al-Ramahi, Abeer Abu Ghoush, Aiman Qaddumi, Yara Abu Zaaror. Weight and content uniformity of Lorazepam

- half-tablets: A study of correlation of a low drug content product. *SPJ*. 2013; 21, 71–75.
7. **Abdel Naser Zaid**, Abualhasan Murad, Qaddumi Aiman, Jodeh Shehdeh. Development of Film Coated Atrovastatin Calcium Tablet Using OPADRY-OYV. *International Journal of Drug delivery*. 2013; 7, 83-91.
 8. Murad N. Abualhasan, Nidal Batrawi, Oliver B. Sutcliffe, **Abdel Naser Zaid**. A Validated Stability-Indicating HPLC Method for Routine Analysis of an Injectable Lincomycin and Spectinomycin Formulation *Sci Pharm*. 2012; 80: 977–986.
 9. Rowa' AL-Ramahi, **Abdel N. Zaid**, Na'em Kettana, Waleed Sweileh, Doa' AL-Jabi. Attitudes of consumers and healthcare professionals towards the patient package inserts - a study in Palestine. Attitudes of consumers and healthcare professionals towards the patient package inserts - a study in Palestine. *Pharmacy Practice* 2012; 10(1): 57-63.
 10. **Zaid AN.**, Qaddumi A. Development and stability evaluation of enteric coated Diclofenac sodium tablets using Sureteric. *Pak J Pharm Sci*. 2012 Jan;25(1):59-64.
 11. Baraldi PG, Baraldi S, Saponaro G, Preti D, Romagnoli R, Piccagli L, Cavalli A, Recanatini M, Moorman AR, **Zaid AN**, Varani K, Borea PA, Aghazadeh Tabrizi. Novel 1,3-Dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl) xanthines as Potent and Selective A2B Adenosine Receptor Antagonists. *J Med Chem*. 2012 Jan 26;55(2):797-811.
 12. **Zaid AN.**, Abu Ghoush A., Al-Ramahi R., Ara'r M. Evaluation of the discrepancy between the European Pharmacopoeia test and the adopted United States Pharmacopoeia test with regard to weight uniformity of scored tablet halves: Harmonization is required. *PDA Journal of Pharmaceutical Science and technology* 2012 Jan 1;66(1):20-7.
 13. **Zaid AN**, Qaddomi A, Khammash S. Formulation and comparative bioavailability of 2 ciprofloxacin sustained release tablets. *Arzneimittelforschung*. 2012 Jul;62(7):319-23.
 14. **Zaid Abdel Naser**, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'. Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets. *Int J Pharm Compd*. 2012 Jul-Aug;16(4):342-6.
 15. **Abdel Naser Zaid**, Rowa' Al-Ramahi, Abeer Abu Ghoush, Numan Malkieh, Maher Kharoaf. Influence of physical factors on tablet splitting, weight and content uniformity of atenolol tablets. *Journal of Pharmaceutical Investigation* (2012) 42:229–234.
 16. Maher Kharoaf, Numan Malkieh, Murad Abualhasan, Raqi Shubitah, Nidal Jaradat, **Abdel Naser Zaid**. Tablet formulation and development of a validated stability indicating HPLC method for quantification of

- valsartan and hydrochlorthiazide combination. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2012, Vol 4, Issue 3, 284-290.
17. Jaradat, Nidal; Jodehb, Shehdeh; Rinno, Tamara; Kharoof, Maher; Naser Zaid, Abdel; Hannon, Mohamed. DETERMINATION THE PRESENCE OF PHYTOMELIN IN ECBALLIUM ELATERIUM TO APPROVE ITS FOLK USES. *Int J Pharm Pharm Sci*, Vol 4, Issue 2, 233-237.
 18. **Abdel Naser Zaid**, Row' Al Ramahi. Knowledge and attitudes of Plaestinain university students toward the use of sunscreens. *Asian Journal of Pharmaceutical and Clinical Research*. 2012.Vol 5, Issue 3,120-122.
 19. **Abdel Naser Zaid**, Ayman Qaddomi, Saed Khammash. Formulation of bifonazole powder and development of a new stability indicating HPLC method for its analysis. *Journal of Pharmacy Research* 2012,5(4),1857-1861.
 20. **Abdel Naser Zaid**, Rowa, Al-Ramahi, Qusai Shahed, Belal Saleh and Josephean Elaraj. Determinants and frequency of pharmaceutical compounding in pharmacy practice in Palestine. *International Journal of Pharmacy Practice*. 2012 Feb;20(1):9-14.
 21. **Abdel Naser Zaid**, Rita Cortesi, Aiman Qaddomi, Saed Khammash. Formulation and Bioequivalence of Two Valsartan Tablets After a Single Oral Administration. *Sci Pharm*. 2011,79 (1) :123-135.
 22. **Zaid AN**, Abu Ghosh. Compliance of scored tablet halves produced by Palestinian pharmaceutical companies with the new European Pharmacopoeia Requirements. *Arch. Pharmcal Res*. 2011. Jul;34(7):1183-9.
 23. Baraldi PG, Preti D, **Zaid AN**, Saponaro G, Tabrizi MA, Baraldi S, Romagnoli R, Moorman AR, Varani K, Cosconati S, Di Maro S, Marinelli L, Novellino E, Borea PA. New 2-Heterocyclyl-imidazo[2,1-i]purin-5-one Derivatives as Potent and Selective Human A3 Adenosine Receptor Antagonists. *J Med Chem*. 2011 Jul 28;54(14):5205-20.
 24. **Abdel Naser Zaid**. Formulation of povidone iodine toothpaste and evaluation of its chemical stability, *Asian Journal of Pharmaceutics*. 2011,5:2, 125-128.
 25. **Zaid A.N.**, Fadda A.M., Nator S.and Qaddumi A. Development and Stability Evaluation of Enteric Coated Diclofenac Sodium Tablets Using AquaPolish E. *Journal of Pharmaceutical Investigation*. 2011, Vol. 41, No. 4, 211-215.
 26. Cortesi R, Romagnoli R, Drechsler M, Menegatti E, **Zaid AN**, Ravani L, Esposito E., Liposomes- and ethosomes-associated distamycins: a comparative study; *J Liposome Res*. 2010 Dec;20(4):277-85.
 27. **Zaid AN**, Abu Ghosh Abeer, Kettane, Weight Uniformity of Scored Tablet Halves Manufactured by Palestinian Pharmaceutical Companies;

International Journal of Pharmaceutical Compounding. 2010May/ June; 257-260.

28. **Abdel Naser Zaid**, Attitude and perception of patients and health care practitioners toward oral sustained release dosage forms in Palestine. *Saudi Pharmaceutical Journal* (2010) 18, 251–25.
29. **Zaid AN**, Cortesi R, Kort J, Sweileh W. Interchangeability of two 500 mg amoxicillin capsules with one 1000 mg amoxicillin tablet after a single oral administration. *Indian J Pharm Sci.* 2010;72(4):414-20.
30. Cortesi R, Ravani L, **Zaid AN**, Menegatti E, Romagnoli R, Drechsler M, Esposito E. Ethosomes for the delivery of anti-HSV-1 molecules: preparation, characterization and in vitro activity. *Pharmazie.* 2010;65(10):743-9.
31. **Zaid AN**, Al-Ramahi R, Abu Ghoush A. Appropriate use of oral drops: perception of health professionals and assessment of package insert information. *Int J Clin Pharmacol Ther.* 2010 Dec;48(12):854-9.
32. Adham S. AbuTaha, Qusai N. Al-Shahed, Waleed M. Sweileh, Ansam F. Sawalha, **Abed Al-Naser Zaid**, Alaeddin O. Abu Zanat1. Vulnerability of cough syrups marketed in Palestine to microbial challenge test. *J. Chem. Pharm. Res.*, 2010, 2(5): 115-121.
33. Tabrizi MA, Baraldi PG, Preti D, Romagnoli R, Saponaro G, Baraldi S, Moorman AR, **Zaid AN**, Varani K, Borea PA. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists. *Bioorg Med Chem.* 2008 1;16(5):2419-30.
34. **A.N. Zaid**, F. Alhaique, J. Cort, W. Sweileh Comparative bioavailability of two cefdinir suspension formulations in Middle Eastern healthy volunteers after single oral administration. *Arzneimittelforschung.* 2008; 58 (3):149-53.
35. Zaid Abdel Naser, Health care practitioners' perceptions of transdermal therapeutic systems in Palestinian territories; *Asian Journal of Pharmaceutics*, 2009; 3 (4) 304-308.
36. Cortesi R. Esposito E., Cuccu I., Romagnoli R., Menegatti E., **A. N. Zaid**. Nastruzzi. Liposomes and micellar dispersions for delivery of benzoheterocyclic derivatives of distamycin a, *Drug Delivery*, 2007;14(1):1-8.
37. **Abdel Naser Zaid**. Formulation and stability evaluation of 1% w/v oral solution of Bromhexin hydrochloride for veterinary use, *The Islamic Un. J.* 2007; 15 (1): 13-22.
38. **Abdel Naser Zaid**, Chemical Stability of Cefotetan Disodium in 0.9% Sodium Chloride Sterile Saline Solutions and Storage in Polypropylene Syringe, *J. Al-Aqsa Univ.*, 11, 2007.

39. **Abdel Naser Zaid**, Abeer O. Abu Ghosh, , Waleed M. Sweileh, Samah W. Al-Jabi, Nidal A. Jaradat, Chewable Tablets: Is this Dosage Form Well Evaluated by Palestinian Health Professionals?, *The Islamic Un. J.*, 2007, 15 (2): 83-94.
40. Sweileh WM, Janem SA, Sawalha AF, Abu-Taha AS, Zyoud SH, Sabri IA, Al-Jabi SW, Jaradat, **NA, Zaid Abdel Naser**. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine. *Pharmacoepidemiol Drug Saf.* 2007 Apr 26.
41. Tichenor MS, Macmillan KS, Stover JS, Wolkenberg SE, Pavani MG, Zanella L, Zaid AN, Spalluto G, Rayl TJ, Hwang I, Baraldi PG, Boger DL. Rational Design, Synthesis, and Evaluation of Key Analogues of CC-1065 and the Duocarmycins. *J Am Chem Soc.* 2007 Oct 19, 129(45):14092-9.
42. P. G. Baraldi. **A. N. Zaid**. et.al. Hybrid molecules based on distamycin A, as a potential antitumor agents, *Arkivoc*, 2006; (vii): 20- 34.
43. **Zaid AN**, Bowirrat A, KOrt JJ, Oscar-Berman M. Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers, *Int J Clin Pharmacol Ther.* 2006, 44(11):593-602.
44. Waleed M. Sweileh[#], Ansam F. Sawalha^{*}, Suha A. Salfeete, Sa'ed H. Zyoud^{*}, Adham S. Abu-Taha, Samah W. Al-jabi, Nidal A. Jaradat and **Abdel Naser Zaid**. Admission Blood Glucose Level as a Potential Indicator for Short Term Mortality and Morbidity after Myocardial Infarction; *International Journal of Diabetes in Developing countries* 2006, 26 (3): 116-121.
45. Sweileh WM, Shkokani FM, Sawalha AF, Al-Ramahi RJ, Jaradat NA, **Zaid AA**, Barakat AS; Prescribing pattern of angiotensin- converting enzyme inhibitors and beta blockers after acute myocardial infarction; *Saudi Med J.* 2005;26(11):1837-9.
46. P. G. Baraldi. **A. N. Zaid**. et.al. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A₃ adenosine receptor antagonists; *J. Med. Chem.* (2005); 48(15):5001-8.
47. P. G. Baraldi. **A. N. Zaid**. et.al. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A₃ adenosine receptor antagonists; *J. Med. Chem.* (2005);48(14):4697-701.
48. P. G. Baraldi. **A. N. Zaid**. et.al. Design, Synthesis and Biological Evaluation of New 8-Heterocyclic Xanthines Derivatives as Highly potent and Selective Human A_{2B} Adenosine Receptor Antagonists; *J. Med. Chem.* (2004). 47:1434-1447.
49. Sweileh WM, . **Zaid**, Jaradat NA; Drug informational Value of Patient Package Insert (PPI): A Sample study in Palestine; *The Islamic Un. J.* 2004; 12 (2): 59-68.

50. P. G. Baraldi, L. A. N. Zaid, et al. A Synthetic Approach for the preparation of rigid Analogs of 1,3-Dipropyl-9-methyl-8-aryl/heteroarylstyryl Xanthines: Synthesis (2001). 5, 773-777.
51. P. G. Baraldi, L. A. N. Zaid, et al. DNA minor-groove binders: results and design of new anti-tumor agents. II Farmaco (1999). 54(1-2). 15-25.
52. P. G. Baraldi, A. N. Zaid, et al. Synthesis and anti HSV-1 activity of 6 substituted pyrazole [3,4-d] pyridazin-7-yl nucleosides. Nucleosides & Nucleotides 1998.17.(12),2165-2173.
53. P. G. Baraldi, L. A. N. Zaid, et al. Heterocyclic analogs of DNA minor groove alkylating agents. Current Pharma. Des. (1998) 4, 263-290.
54. P. G. Baraldi, A. N. Zaid, et al. Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of adenosine A₁ receptor. Bioorganic and Medicinal Chemistry Letters (2000) 10, 1953-1957.
55. P. G. Baraldi, A. N. Zaid, et al. A new synthetic approach to indazoles synthesis. Synthesis (1997) 1140-1142
56. P. G. Baraldi, A. N. Zaid, et al. Pyridazine nucleus: A pharmacophoric moiety/or bio-active compounds. APhco (1996)66,S35-S38.
57. P. G. Baraldi, A. N. Zaid, et al. Synthesis, Solvolytic stability and cytotoxicity of modified derivative of Cpzl, a pyrazole analog of the alkylation sub-unit of the anti-tumor agent CC-1065: effect of the nitrogen substitution on the functional reactivity. II Farmaco (1997) 52, 717-723.
58. P. G. Baraldi, A. N. Zaid, et al. Synthesis cytotoxicity and anti-tumor activity of some new simplified pyrazole analogs of the anti-tumor agent CC-1065. Effect of an hydrophobic group on anti-tumor activity. II Farmaco (1997). 52. 711-716

Meeting presentation:

1. P. G. Baraldi, A. N. Zaid, et al (1995). Synthesis, Chemical solvolysis stability and biological evaluation of (+,-) Cpzl: a pyrazole analog of the left hand segment of anti tumor agent CC-1065. *The Italian -Spanish meeting in Pharmaceutical Chemistry*, Ferrara August 30-September 3.
2. P. G. Baraldi, A. N. Zaid, et al. (1996). *Pyrazole analogs of CC-1065: High cytotoxic compounds with high sequence selectivity to the DNA*. XIX National congress "Research & Technology" Riccioni, Italy, June, 9-14.
3. P. G. Baraldi, A. N. Zaid, et al (1996). Synthesis, chemical solvolytic stability and preliminary biological evaluation of pyrazole analogs of the natural anti tumor agent CC-1065 and duocramycin. Eight Fechem Conference on Heterocycles in Bio-Organic Chemistry, Villa Oimo

- (Como), Italy, September, 1-4.
4. P. G. Baraldi. A. N. Zaid. et.al (1996). Synthesis solvolytic stability and biological evaluation of pyrazole analogs of the natural anti tumor agent CC-1065. 1065 and duocramycin. XII National Meeting - Division of Italian Pharmaceutical and Chemical Society. Italy Pastum, September 23-27.
 5. P. G. Baraldi. A. N. Zaid. et.al (1996). Pyridazine nucleus: a pharmacophoric moiety. for bio-active compounds. 5th International Symposium on the Chemistry and Pharmacology of Pyridazines. Hungary, Sopron. October, 2-5.
 6. P. G. Baraldi. A. N. Zaid. et.al (1997). Synthesis and biological evaluation of some Heteroaryl Analogs of the Anti tumor Agents CC-1065 and Duocarmycin. 6th Ibn Sina International Conference on Pure and Applied Heterocyclic Chemistry. Cairo, Egypt, December, 13-16.
 7. P. G. Baraldi. A. N. Zaid. et.al. (1998). Structure-activity relationship of one class of substituted -2-amino-3-benzoyl-thiophenes as A1 adenosine receptor modulator. 6th International Symposium on Adenosine and Nucleotides. New frontiers in the 3' millennium. Italy, Ferrara- May 19-24.
 8. P. G. Baratdi. A. N. Zaid . et al. (2001). Synthesis Y Perfil Biologico De Analogos Pirazolicos Relacionados con El Agente, Antitumoral, CC-1065 Y Adozelezina. Novas aproximacoes, para a descoberta de fannacos. Possibilidades e limitacoes na America Latina. Brazil Rio de Janeiro, 24 de Agosto2001.
 9. P. G. Baraldi. A. N. Zaid . et al. (2001). Diseno, Sintesis Y Evaluacion Biologica De Nuevos Ligandos Del Receptor A3, De La Adenosena - Novas aproximacoes, para a descoberta de fannacos. Possibilidades e limitacoes na America Latina. Brazil Rio de Janeiro, 24 de Agosto 2001.
 10. WHO, Workshop on bioequivalence. (2009) Ramallah-Palestine .
 11. PFDP seminar for excellence in teaching. (2011) Ramallah-Palestine.
 12. The first Palestinian conference on nanotechnology. (2012) An Najah National University, Nablus-Palestine.
 13. UEA School of pharmacy Research Day. (2012) UEA- United Kingdom.
 14. UEA School of Chemistry – Annual Research Colloquium. (2012) UEA- United Kingdom.
 15. The 7th Annual International Chemistry Conference, Palestinian. (2013). Birzeit University, Ramallah- Palestine.
 16. The First Global Conference of Palestinian Academics in the Diaspora. (2013) An Najah National University, Nablus-Palestine.

Teaching Experiences

1998- 2002. Assistant professor at Al - Quds University, College of Health Profession, Science & technology. He taught the following courses:

	Pharmaceutical Technology, Organic chemistry, Laboratory of pharmaceutical Technology, Cosmetics, Laboratory of cosmetics, Pharmacology, Anatomy & Physiology, Biology.
2002 – 2008	Assistant professor at An-NaJah National University, College of Pharmacy. Teaching the following courses: Pharmaceutics; (I, II, & III), Medicinal chemistry, Pharmaceutical Calculations (Master degree), Cosmetics, Pharmaceutical Excipients, Pharmaceutical sterilization.
2008 - Tel now	Associate professor at An-NaJah National University, College of Pharmacy.

Working Experiences:

1999 - 2001	Supervisor of the Pharmaceutical formulation team at Pharmacare Ltd. Ramallah, West Bank - Palestine.
2001 - now	Consultant at Pharmacare Ltd. Ramallah, West Bank - Palestine.
2001- 2011	Consultant at Al-Wafa Medical & Veterinary Manufacturing Co. Ltd. Nablus, West Bank - Palestine.

Research Collaboration: Currently cooperates with the following groups of research:

- Group of professor B.G. Baraldi (Ferrara University, Italy) on the synthesis and development of novel drugs in the field of Cancer, Adenosine receptor (antagonists & agonists) & Neuropathic pain.
- Group of professor R. Cortesi (Ferrara University, Italy) on the development of liposomes & ethosomes.
- Group of professor F. Vincieri (Firenze University, Italy) on the traditional Arab medicine.

Inventions: Inventor of T 62, a novel drug for neuropathic pain, which is currently in phase iii studies, for King Pharmaceutical, Triangle Park, North Caroline, USA.

Membership: Member of the drug registration comity of the Palestinian Ministry of Health.

Professional Experiences:

- 2013, Jun 16-July 16 Research, in the laboratory of Professor Francesca Baldelli Bombelli, about the synthesis of Gold nano particles, (UEA, United Kingdom).
- 2007, Jun.1 – Aug.1 Research, in the laboratory of professor Baraldi & Cortesi, about the development of stable prodrugs & development of lyposoaml systems for bioavailability enhancement, (University of Ferrara, Italy).
- 2004, Jun.1 -Aug.1 Visiting Professor in the Specialization School of Cosmetic Sciences & Technologies, working on the problems of formulation technology of cosmetics preparation, (University of Ferrara, Italy).
- 2001, Jun. 1-Sept. 1 Visiting Professor in the Specialization School of Cosmetic Sciences & Technologies, working on the effect of cosmetics preparations on the Skin of human volunteers, (University of Ferrara, Italy).

Training Experiences:

- 1997 - 1995. External Training in the Specialization School of Cosmetic Sciences & Technologies, working on the formulation of cosmetic preparation, (Ferrara University, Italy).
- 1997 1-5 July Attendance of XVI advanced course in Pharmaceutical Technology in Urbino University (Ps, Italy).
- 1996, 2-6 July Attendance of XVI advanced course in Pharmaceutical Technology in Urbino University (Ps, Italy).
- 1995, 3-7 July Attendance of XV advanced course in Pharmaceutical Technology in Urbino University (Ps, Italy).

References

- 1- Professor P.G. Baraldi Full Professor of Pharmaceutical Chemistry
Dept of Pharmaceutical Sciences
University of Ferrara
ViaFossato di Mortara,17-19
44100 Ferrara Italy Tel.:+39-0532-291293
Telefax: +39-0532-291270
E-mail: brlpgv@pop3.unife.it
- 2- Professor S. Tanganelli Full Professor of Pharmacology

Dept of Clinical and Experimental Medicine
Section of Pharmacology
University of Ferrara
Via Fossato di Mortara,17-19
44100 Ferrara Italy
Tel.:+39-0532-291212
Fax:+39-0532-291205, E- mail: [FRL@IFEUNIV.UNIFE.tT](mailto:FRL@IFEUNIV.UNIFE.IT)

3- Professor R. Cortesi, Associate Professor of Pharmaceutical technology,
Dept. of Pharmaceutical Sciences University of Ferrara
ViaFossato di Mortara,17-19
44100 Ferrara Italy
E-mail: crt@unife.it

4- Professor F. Alhaique
Department of “Studi di Chimica e Tecnologia
delle Sostanze Biologicamente Attive”
Faculty of Pharmacy, University “La Sapienza”
Piazzale Aldo Moro 5, 00185 Rome, Italy
E-mail: franco.alhaique@uniroma1.it